Categories: Health

Initiation of share buyback program

On March 5, 2025, Novonesis will initiate a share buyback program as announced in Company Announcement No. 3 of February 26, 2025. Under the program, Novonesis will buy back B shares worth up to EUR 100 million in total during the remainder of 2025, corresponding to around 1.7 million B shares at the current share price. The program is contingent upon no major strategic initiatives being decided upon that will require a significant amount of capital.

The shares acquired in the program will be used to meet obligations arising from employee share-based incentive programs.

The maximum number of shares to be purchased by the company per daily market session will be equivalent to no more than 25% of the average volume of shares in the company traded on NASDAQ OMX Copenhagen during the preceding 20 business days. The program will run in accordance with the European Commission Regulation (EU) No. 596/2014 of 16 April 2014 (the “Market Abuse Regulation”), and the European Commission Delegated Regulation (EU) No. 1052/2016 of 8 March 2016 (the “Safe Harbour Regulation”).

GlobeNews Wire

Recent Posts

Renowned Biomedical Scientist Franco Cavaleri Challenges Conventional Alzheimer’s Theories in Groundbreaking Study

VANCOUVER, British Columbia, March 31, 2025 (GLOBE NEWSWIRE) -- Franco Cavaleri, B.Sc., Ph.D.c, a distinguished…

3 hours ago

Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order

March 31, 2025 20:10 ET  | Source: Avicanna Inc. Auditor Licensing & Personnel Issues Delays…

3 hours ago

Scientific Industries Reports Financial Results for Fiscal Year Ended December 31, 2024 and Launches DOTS MPS for Cell Culture Biopharma Market

BIOPROCESSING OPERATIONS: 24% REVENUE GROWTH DRIVEN BY NEWLY LAUNCHED PRODUCTS OPERATIONAL EFFICIENCIES CUT TOTAL NET LOSSES…

3 hours ago

Total number of shares and voting rights in Zealand Pharma as of March 31, 2025

March 31, 2025 17:00 ET  | Source: Zealand Pharma Company announcement – No. 8 /…

3 hours ago

Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights

Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive…

3 hours ago

Firstever joint Chefs de Mission Seminar provides key insights into Milano Cortina 2026 preparations

31 March 2025 - Delegations from around the world gathered in Milan from 24 to 30…

4 hours ago